+152.4%
DKNG vs MRNA
+892.2%
-739.8%
-85.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.3% | +5.4% | -1.0% | +3.8% |
| 7D | +3.0% | -1.1% | +4.1% | +3.2% |
| 30D | -3.0% | +126.1% | -129.1% | -18.5% |
| 3M | -17.6% | +190.0% | -207.6% | -34.1% |
| 6M | -3.2% | +157.2% | -160.5% | -21.6% |
| YTD | -28.2% | +388.2% | -416.4% | -48.6% |
| 1Y | -46.1% | +467.0% | -513.1% | -62.8% |
| 3Y | -22.2% | +36.1% | -58.3% | -35.1% |
| 5Y | -60.4% | -68.0% | +7.6% | -62.1% |
| All | +152.4% | +892.2% | -739.8% | +98.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling